www.fdanews.com/articles/197071-lynparza-approved-as-maintenance-treatment-for-ovarian-cancer
Lynparza Approved as Maintenance Treatment for Ovarian Cancer
May 12, 2020
The FDA has approved AstraZeneca’s and Merck’s Lynparza (olaparib) in combination with bevacizumab as a maintenance treatment for adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
The approval was based on the results of a phase 3 clinical trial, which showed that the combination reduced the risk of disease progression or death by 67 percent.
Lynparza was previously approved as a maintenance treatment of platinum-sensitive relapsed ovarian cancer.